Collegium reports FDA filing for rhinitis drug

AllerNase (triamcinolone acetonide) nasal spray, an aqueous based intranasal steroid is indicated for the once daily treatment of nasal symptoms associated with both seasonal and perennial allergic rhinitis in adults and children twelve years of age and older.

Michael Heffernan, president of Collegium, said: “We believe that the benefits of AllerNase’s novel aqueous based solution formulation containing a proven safe and effective active ingredient (triamcinolone acetonide) will provide another alternative to the currently available options for the treatment of allergic rhinitis. We intend to direct our focus on identifying the best commercial marketing partner for the product.”